Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74622

Title: Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03120111
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer's Country/Territory: China
Author's Country/Territory: Brazil

Manuscript submission date: 2021-12-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-02 12:53

Reviewer performed review: 2022-01-02 13:28

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This submission was to address the effects of PPAR-alpha activation and DPP-4 inhibition upon the gut-liver axis, emphasizing inflammatory pathways in MAFLD management in high-fat-fed C57BL/6J mice.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74622

Title: Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04740911
Position: Peer Reviewer
Academic degree: MD, MSc, PhD
Professional title: Assistant Professor, Research Scientist
Reviewer's Country/Territory: Poland
Author's Country/Territory: Brazil

Manuscript submission date: 2021-12-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-02 12:49

Reviewer performed review: 2022-01-11 17:22

Review time: 9 Days and 4 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript of "PPAR-alpha activation and DPP-4 inhibition target gut dysbiosis and inflammation to treat MAFLD in diet-induced obesity" cover up to date, very important topic. Hovewer, I would add in the title ... in diet inducet obesity mice, as the work has been done on mice not on humans. Abstract and key words summarize and focus on the work described in the manuscript. In the background authors add sentence about COVID-19 pandemic - in my opinion it is usless. Was this only for the reference 3? Other sententes in the introduction are well prepared and describe the most important things I need to know about the manuscript. Methods. In the methods autors describe the oral glucose tolerance test - but the WHO recommend to measure the glucose in the plasma of the blood and the manual glucometer (which was used by the authors) is for the glucose level in the whole blood. So the methods should be also described in the end of the discussion as the part of limitation of the study. Moreover the authors describe the Trayenta - the linagliptin drug which is DPP-4 inhibitor, I would delete the name of the "Trayenta" as a name of Boehringer Ingelheim International drug. Results the results re properly described and are repeatable. The discussion is clear and in logical manner interpret the results and adequatly highlit the novelty of the experiments. The figures are well prepared and described, however the same as in the methods, and results I would delete the Trayenta name. Minor points. Grammar and spelling should be checked (eg. increased insulin sensitiveness - increased insulin sensitivity). I recommednt to publish the manuscript after minor revision.